Fda grants soligenix orphan drug designation for the prevention and post-exposure prophylaxis against marburg marburgvirus infection

Provides marvax™ heat stable vaccine seven years of u.s. market exclusivity upon fda approval  princeton, n.j. , april 15, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the office of orphan products development of the united states (u.s.) food and drug administration (fda) has granted orphan drug designation to the active ingredient in marvax™, the subunit protein vaccine of recombinantly expressed marburg marburgvirus (marv) glycoprotein, for "the prevention and post-exposure prophylaxis against marv infection.
SNGX Ratings Summary
SNGX Quant Ranking